Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Ovarian cancer is a group of complex and rare cancers with one of the lowest survival rates in Australia It is generally diagnosed at an advanced stage because women accept pelvic pain as a normal ...

Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the following: More recent biopsies are preferred for testing ...

Ovarian cysts, which are small fluid-filled sacs that develop in or on the ovaries, are very common and are usually harmless.

Spence has taken to her TikTok page, followed by 11k users, to highlight five 'red flag' symptoms that could indicate serious ...

Since she enrolled in a clinical trial at MSK to treat her low-grade serous ovarian cancer, Ellen Coopersmith has a new outlook on life. The first drug for a rare and difficult-to-treat type of ...

including vision impairment and pain, the news nonetheless saw a share price rise of nearly 8% to $6.20 before the bell. AbbVie hopes for another lift to its fast-growing ovarian cancer drug ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Ovarian cancer is an abnormal cell growth (tumour) arising in the ovary. The majority of ovarian cancers are epithelial and develop in women over 50. Screening is highly recommended in women with ...

An investigative history of the scandal-plagued company shines a light on a health care industry riddled with corruption and ...

Clovis' Rubraca is on the verge of approval in Europe in women with advanced ovarian cancer, after regulators gave it the green light. The European Medicines Agency’s CHMP scientific committee ...